Opendata, web and dolomites

EBOVAC2 SIGNED

Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen: Phase II - Sofia ref.: 115861

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EBOVAC2" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.ebovac2.com/
 Total cost 50˙710˙893 €
 EC max contribution 22˙790˙820 € (45%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2014
 Duration (year-month-day) from 2014-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 15˙650˙912.00
2    CENTRE MURAZ BF (BOBO-DIOULASSO) participant 3˙782˙783.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 2˙041˙083.00
4    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER UK (LONDON) participant 888˙951.00
5    INSERM - TRANSFERT SA FR (PARIS) participant 427˙090.00
6    JANSSEN VACCINES & PREVENTION BV NL (LEIDEN) participant 0.00

Map

 Project objective

The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBOV and MVA-BN-Filo vaccine.

This will be done by: 1. Carrying out translational studies to link vaccine elicited immune responses in humans to protection from Ebola in vaccinated non-human primates (via WP4) 2. Carrying out Phase II trials in African and European volunteers in 6 countries, four in Africa and two in the EU with an overall target enrolment of approximately 1,500 subjects. Given the compressed nature of this development program, the Phase II studies will be conducted in parallel with the planned Phase III study (EBOVAC1). The phase II studies will be placebo-controlled and will be conducted in locations where it is possible to perform carefully controlled safety studies (via WP2). 3. Evaluating the use of the vaccine in special population groups, such as children (ages 1-17 years), the elderly (ages 50-65) and individuals infected with HIV, to confirm safety and immunogenicity. It is intended that Phase II trials will begin as soon as safety data are available from Phase I trials (via WP2). 4. Monitoring and characterising immune response to the proposed vaccine (via WP3). 5. Boosting the capacity of African centres, staff and infrastructure in preparation for Phase III studies and communicating and disseminating widely the results of EBOVAC2 as they become available to all key stakeholders (via WP6). 6. Contributing all data to the Central Information Repository for use by other Ebola programme projects as well as the wider community (via WP5).

 Deliverables

List of deliverables.
Capacity-building implementation report Documents, reports 2019-11-15 10:09:23
1st EBOVAC2 e-newsletter Other 2019-11-15 10:09:23
Communication tools Other 2019-11-15 10:09:23
Ebola project clustering activity plan Documents, reports 2019-11-15 10:09:23
Capacity-building programme Documents, reports 2019-11-15 10:09:23

Take a look to the deliverables list in detail:  detailed list of EBOVAC2 deliverables.

 Publications

year authors and title journal last update
List of publications.
2016 Barry H, Valéa I, Berthé A, Lougué G, Tinto H, Thiébaut R, et al.
1-Barrières et facilitateurs de la mise en oeuvre d’un essai vaccinal en situation d’urgence: cas de l’essai EBOVAC2 au Burkina Faso.2- Barriers and facilitators in implementin g a vaccine trial in emergency situation: the case of EBOLA Vaccine Phase II Trial (VAC52150 EBL2002) in Burkina Faso
published pages: , ISSN: , DOI:
3-6 may 2016; 26 to 28 May 2016 2019-11-15

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOVAC2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOVAC2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More